

Longjumeau, April 22, 2014

Net sales

<i>(in thousands of euros)</i>	2013	2014	% change
Sales as of 31 March	43 033	42 053	-2,3%
<i>including Pharmaceutical Synthesis</i>	<i>26 677</i>	<i>27 117</i>	<i>1,6%</i>
<i>including Fine Speciality Chemicals</i>	<i>16 356</i>	<i>14 936</i>	<i>-8,7%</i>

Consolidated net sales for the PCAS Group are down 2.3% in the first quarter of 2014 compared to the same period for the previous year.

Pharmaceutical synthesis

Pharmaceutical Synthesis activities are continuing to develop in 2014, up 1.6% compared to the first quarter of 2013.

Fine Specialty Chemicals

Fine Specialty Chemicals net sales are down 8.7% compared to the first quarter of 2013, but up 23% compared to the last quarter of 2013.

Next meeting:

Shareholders' meeting
April 23, 2014, 10.00 a.m. in Longjumeau

About PCAS:

Founded in 1962, PCAS is an international fine and specialty chemicals group (165 million € net sales in 2013) that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability. PCAS also develops ranges of proprietary products based on intellectual property.